PTSD stands for post-traumatic stress disorder, a trauma-related psychiatric disorder that can develop after exposure to traumatic events and is marked by intrusive memories, avoidance, negative mood/cognition changes, and hyperarousal.
Silo Pharma received a European patent grant and a Japan patent allowance for SPC-15, its intranasal PTSD prevention candidate. The patents cover methods using serotonin 4 receptor agonists to prevent stress-induced psychiatric disorders.
Oral semaglutide cut heavy drinking and cravings in an 8-week AUD trial. The VA is testing semaglutide in the CRAVE trial enrolling more than 600 veterans.
FDA final guidance sets standards for psychedelic clinical trials. Federal agencies and states are advancing psilocybin and ibogaine research, and Eli Lilly is acquiring AtaiBeckley for $2.8 billion.
Studies reveal context-dependent genetic effects in psychiatric disorders, reassuring evidence on prenatal antidepressant use, and findings on parental depression timing, diagnostic interview reliability, and rising self-diagnosis.
The Trump administration is reclassifying medical marijuana from Schedule I to Schedule III and accelerating psychedelic research with a $50 million executive order. The FDA commissioner says marijuana has medical benefits but warns of potency and risks to youth. The DEA says the rescheduling process remains pending.
Otsuka Pharmaceutical said its U.S. subsidiary plans to acquire Transcend Therapeutics for $700 million, with up to $525 million more tied to sales milestones. The deal would add TSND-201, a methylone-based PTSD drug now moving into Phase 3 testing in the U.S.
Enveric Biosciences reports positive preclinical results for lead candidate EB-003 showing efficacy in depression and PTSD models. The company has completed pre-IND studies and received FDA feedback for streamlined IND submission, with plans for Phase 1 trials in 2026. New BRET assay data demonstrates EB-003's engagement of therapeutic signaling pathways while independent research supports separation from hallucinogenic effects.
The American Psychiatric Association will include biomarkers in the next DSM edition, though such markers remain unvalidated for routine clinical use. Research has spanned decades with limited adoption despite potential to guide treatment selection.
New research reveals how ketamine rewires brain receptors to rapidly relieve severe depression, while separate trials demonstrate success with personalized brain stimulation and targeted drug therapy for treatment-resistant cases.
Compass Pathways announced positive Phase 3 data for COMP360 psilocybin therapy in treatment-resistant depression, showing statistically significant improvements in depression scores and durability through 26 weeks, with plans to file for FDA approval in Q4 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07771530 |
The Efficacy of a Pharmacological Treatment (Reboxetine Plus Ritalin) Versus Dog-Assisted Therapy in PTSD |
RECRUITING | PHASE2 |
| NCT07745569 |
Assessing of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies |
NOT_YET_RECRUITING | PHASE2 |
| NCT07712796 |
Empowerment Self Defense Program for Adult Native Women Survivors of Sexual Violence |
NOT_YET_RECRUITING | NA |
| NCT07710417 |
FLOAT for Healthcare PTSS |
RECRUITING | EARLY_PHASE1 |
| NCT07704762 |
Clinical Trial of MDMA-Assisted Therapy for Military Service Members With Posttraumatic Stress Disorder |
NOT_YET_RECRUITING | PHASE2 |
| NCT07680517 |
Examining the Efficacy of Short-Term Intensive PTSD Treatment on Psychological and Cognitive Impairment Symptoms |
RECRUITING | NA |
| NCT07664631 |
Effects of Stimulant Medications in PTSD |
NOT_YET_RECRUITING | PHASE1 |
| NCT07658157 |
Exposure by Assessment: Effects of Daily AMQ-Based EMA of an Intrusive Trauma Memory in PTSD |
RECRUITING | NA |
| NCT07652645 |
Hybrid Dialectical Behavior Therapy for Veterans to Further Reduce Emotion Regulation Problems and Trauma Symptoms |
RECRUITING | NA |
| NCT07645274 |
Improving Mental Healthcare Outcomes for Minoritized Veterans Through a Peer-led, Patient Navigation Program (PARTNER-MH 2.0) |
NOT_YET_RECRUITING | NA |
